Hamburg, Germany — Urology specialists from across Europe, the Middle East and Africa convened at the BPH Innovations Forum 2025, hosted at the Olympus EMEA Headquarters in Hamburg. Now marking its tenth year, the forum has established itself as a key educational and networking platform dedicated to advancing the management of benign prostatic hyperplasia (BPH).
The two-day programme brought together over 100 urologists and healthcare professionals for in-depth discussions, expert-led sessions, and hands-on training focused on contemporary and emerging BPH treatment pathways. This year’s agenda placed particular emphasis on iTind, PLASMA, and SOLTIVE technologies, reflecting the growing clinical interest in minimally invasive, tissue-sparing solutions for men with lower urinary tract symptoms.
Attendees participated in a blend of scientific lectures, semi-live procedural demonstrations, and practical workshops designed to support real-world clinical adoption. Topics included optimising patient selection, integrating day-case surgery models, use of local anaesthesia, and strategies for safely expanding minimally invasive BPH services within both NHS and private practice settings.
A strong focus was placed on shared learning and collaboration, with clinicians exchanging insights on outcomes, workflow efficiencies, and patient-centred care. The forum also provided opportunities for direct engagement with Olympus clinical specialists, enabling delegates to gain hands-on experience with the latest technologies and discuss implementation challenges in different healthcare systems.
Commenting on the event, Jeremy Nettleton highlighted the importance of industry-supported education in accelerating safe innovation and improving standards of care across urology services.
The BPH Innovations Forum 2025 reinforced Olympus’s ongoing commitment to supporting the urology community through education, innovation, and collaboration—helping clinicians stay at the forefront of minimally invasive BPH treatment and ultimately improve patient outcomes across the EMEA region.
